| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 54.5 | 104.3 |
| Gross profit | 30.0 | 93.1 |
| Profit before tax | -16.4 | 52.6 |
| Net income | -14.7 | 108.6 |
| EPS (diluted, $ a share) | $-0.19 | $1.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -47.7% |
|---|---|
| Gross margin | 55.0% |
| Operating margin | -12.1% |
10-Q filed with the SEC, NASDAQ: CRMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CorMedix Inc.: key numbers
- Share price
- $4.82Close, Nov 16
- Market cap
- $383M
- Shares outstanding
- 79.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CorMedix Inc.
All →CorMedix CEO Joseph Todisco Buys $391K of Stock
Joseph Todisco, CEO, bought 80,000 shares of CorMedix Inc. at $4.89 a share, worth $391K in total on Nov 13, 2026. Shares held after the trade: 854,749 (+10.3%).
- Value
- $391K
- Shares
- 80,000
- Price
- $4.89
- Role
- CEO
- Holding change
- +10.3%
- Trade date
- Nov 13, 2026
CorMedix M&A Deal with Heron Therapeutics, Inc.
CorMedix Inc. announced a definitive agreement to acquire substantially all of the assets of Heron Therapeutics, Inc., including both commercial and pipeline assets. The acquisition is intended to provide scale and diversification to CorMedix's institutional care growth strategy and remains subject to Heron stockholder approval and regulatory clearance.
- Counterparty
- Heron Therapeutics, Inc.
CorMedix Financial Results
CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, while maintaining its full-year 2026 revenue guidance. The company also highlighted its pending acquisition of Heron Therapeutics assets and a new $150 million term loan facility to support the transaction and operations.
- Term
- Q3 2026
“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing.”
Joseph Todisco, Chairman & Chief Executive Officer
CorMedix M&A Deal with Heron Therapeutics, Inc.
CorMedix Inc. has entered into a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics. The transaction will be funded in part through a new term loan facility with Pharmakon and the issuance of CorMedix common stock as consideration. The deal is expected to be accretive to earnings and free cash flow while providing operating cost synergies.
- Counterparty
- Heron Therapeutics, Inc.
CorMedix Signs $145M M&A Deal with Heron Therapeutics, Inc.
CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.
- Value
- $145M
- Counterparty
- Heron Therapeutics, Inc.
CorMedix Business Update
CorMedix provided a business update reporting a cash position of approximately $355 million as of September 30, 2026, and reaffirmed its full-year 2026 revenue guidance. The company also addressed the CMS 2027 ESRD PPS final rule regarding DefenCath reimbursement, projecting that the average 2027 Add-on rate will be more than double the current rate.